

Evaluation of the Relationship Between Thrombolytic Treatment Complications and Laboratory Parameters in Acute Ischemic Stroke Patients

Mustafa Çalık¹, Derya Öztürk²

¹University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital, Clinic of Emergency Medicine, İstanbul, Turkey

²University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital, Clinic of Emergency Medicine, İstanbul, Turkey

Cite this article as: Çalık M, Öztürk D. Evaluation of the Relationship Between Thrombolytic Treatment Complications and Laboratory Parameters in Acute Ischemic Stroke Patients. J Acad Res Med 2022;12(1):36-41

ABSTRACT

Objective: We aimed to investigate the role of serum uric acid and lactate levels and mean platelet volume in predicting treatment success in patients with ischemic stroke.

Methods: One hundred and five patients who were diagnosed with cerebrovascular disease and received thrombolytic or thrombectomy treatment were included in the study. Patients were divided into two groups as patients who developed complications and who did not develop complications. Demographical characteristics, laboratory findings, the National Institutes of Health Stroke Scale (NIHSS) scores at admission and at discharge, and Modified Rankin Scale (mRS) score were investigated retrospectively.

Results: Of all patients, 58.1% of the were male. There were no differences in terms of laboratory parameters between the groups. NIHSS score at admission, NIHSS score at discharge, and mRS score were significantly higher in the group that developed complications after treatment ($p<0.05$). Laboratory values did not differ significantly between the groups. Early mortality rate in the group which developed complications was significantly higher than the group which did not develop complications ($p<0.05$). Univariate model revealed significant effectiveness of NIHSS score at admission and at discharge, and mRS score in the differentiation of patients with and without complications ($p<0.05$). In the multivariate model, a significant and independent effectiveness of the NIHSS score at discharge was observed in the differentiation of patients with and without complications (sensitivity =83.3%, positive prediction =30.8%, specificity =57.1% and negative prediction =93.8%; $p<0.05$).

Conclusion: We found no significant associations between the development of complications after thrombolytic therapy and laboratory findings. The NIHSS score may be a suitable parameter in predicting complications.

Keywords: Acute cerebral ischemia, lactate, NIHSS score, Modified Rankin Scale, uric acid

ORCID IDs of the authors: M.Ç. 0000-0002-3184-2943; D.Ö. 0000-0001-7318-0725.

Corresponding Author: Mustafa Çalık,

E-mail: drmustafacalik@yahoo.com



Received Date: 24.11.2021 Accepted Date: 25.02.2022

©Copyright 2022 by University of Health Sciences Turkey, Gaziosmanpaşa Training and Research Hospital. Available on-line at www.jarem.org

INTRODUCTION

Acute cerebrovascular event (ACE) is a condition with permanent brain damage because of disruption of cerebral blood flow. Even though ACE is the second most common cause of mortality and the leading cause of disability worldwide, making decisions about the clinical course and predicting prognosis of ischemic stroke (IS) patients are still challenging (1-3).

A clinically significant relationship between serum uric acid levels and cardiovascular and cerebrovascular diseases (CVDs) has been shown (4,5). Hyperuricemia is often observed in patients with metabolic syndrome and the risk of vascular diseases is high in metabolic syndrome (6,7). Poor clinical picture after ACE has been implicated to be associated with hyperuricemia (8). There are studies showing that uric acid is a powerful antioxidant against free radicals (9,10), however, high serum uric acid levels are indicated as an independent risk factor for the development of cerebrovascular and cardiovascular disease (11). Lactate is a known by-product of anaerobic metabolism and is increased upon hypoperfusion (12). Hyperlactatemia is a biomarker of metabolic stress response and is found to be associated with mortality in critically ill patients (13,14). Several previous magnetic resonance spectroscopy and microdialysis studies have shown that lactate accumulates in ischemic brain lesions in acute stroke patients (15,16).

In our study, we aimed to investigate the role of serum uric acid and lactate levels and mean platelet volume (MPV), as well as the National Institutes of Health Stroke Scale (NIHSS) score at admission, NIHSS score at discharge, and Modified Rankin Scale (mRS) score in predicting treatment success in patients with IS.

METHODS

This retrospective study was conducted on patients who were admitted to University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital Emergency Service within a 2-year period (between 01.01.2018-01.01.2020), diagnosed with CVD, and treated with only thrombolytic, only thrombectomy or thrombolytic + thrombectomy therapies in the emergency department and hospitalized in the neurology clinic of our hospital.

The blood pressure category (normal, stage I hypertension and stage II hypertension), electrocardiogram (ECG) and echocardiogram (ECHO) findings, presence of comorbidity, blood parameters [haemoglobin (HGB), MPV, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet (PLT) and red cell distribution width (RDW) values], serum uric acid and lactate levels, the NIHSS scores at admission and discharge, and mRS score were analysed in patients with regards to the presence of complications. This study was conducted in accordance with the Declaration of Helsinki on Ethical Principles. Ethical approval was obtained from University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee (decision no: 2688, date: 25.02.2020).

Statistical Analysis

In the descriptive statistics of the data, mean, standard deviation, median, minimum, maximum, frequency and ratio values were used. The distribution of variables was analysed with the Kolmogorov-Smirnov test. Independent samples t-test and Mann-Whitney U test were used in the analysis of quantitative independent data. Chi-square test was used in the analysis of qualitative independent data while Fisher's Exact test was used when the chi-square test conditions were not met. The effect level and cut-off value were investigated with the Receiver operating characteristic curve. The effectiveness of the NIHSS scores and mRS score in discriminating the complication status of the patients was investigated with univariate and multivariate logistic regression. The SPSS 26.0 program was used in the analysis.

RESULTS

A total of 105 patients were included in the study. Of the patients, 61 (58.1%) were male and 44 (41.9%) were female. Distribution of the comorbid diseases and demographic characteristics are indicated in Table 1.

The condition of blood pressure and ECG and ECHO findings did not differ significantly ($p>0.05$) between the groups with and without complications after thrombolytic therapy (TT). At the post-treatment period, patients who developed complications had significantly higher NIHSS score both at admission and at discharge and higher mRS score compared to the patients who did not develop any complications ($p<0.05$; Table 2). HGB, PLT, NLR, PLR, RDW, MPV, lactate, and uric acid values did not differ significantly between the groups with and without complications after treatment ($p>0.05$). The early mortality rate in the group with complications was significantly higher than the group without complications ($p<0.05$) (Table 2). Moreover, there were no significant associations between the presence of complications

Table 1. Demographic characteristics of patients

		Complication (-)	Complication (+)	p
		n (%)	n (%)	
Age	≤64	31 (29.5)	5 (20.8)	0.392 ^x
	≥65	74 (70.5)	19 (79.2)	
Gender	Female	44 (41.9)	8 (33.3)	0.440 ^x
	Male	61 (58.1)	16 (66.7)	
Comorbid chronic disease	(-)	16 (15.2)	3 (12.5)	0.733 ^x
	(+)	89 (84.8)	21 (87.5)	
Comorbid chronic disease	IHD	45 (42.9)	10 (41.7)	0.915 ^x
	HT	71 (67.6)	17 (70.8)	0.760 ^x
	DM	25 (23.8)	8 (33.3)	0.335 ^x
	CVE	19 (18.1)	5 (20.8)	0.756 ^x
	Other	18 (17.1)	4 (16.7)	0.955 ^x

CVE: cerebrovascular event, DM: diabetes mellitus, HT: hypertension, IHD: ischemic heart disease, ^xSpearman Rho test

and the duration of the treatment ($p>0.05$; Table 2a and Table 2b). In the analysis with univariate model, significant efficiencies of NIHSS score at admission, NIHSS score at discharge, and mRS score was observed in distinguishing patients with and without complications. In the analysis with reduced multivariate model, a significant and independent efficiency of the NIHSS score at discharge was observed in discriminating patients with and without complications (odds ratio: 1.17, 95% confidence interval: 1.07-1.28, $p=0.001$) (Table 3).

A significant efficacy of the NIHSS score at discharge was observed in the discrimination of patients who developed and

did not develop complications after treatment [Area under the curve (AUC) =0.766 (0.661-0.872)]. A significant efficacy of the cut-off value of 10 in the NIHSS score at discharge was observed in the differentiation of patients with and without complications [AUC =0.702 (0.595-0.810)]. Sensitivity, positive prediction, specificity, and negative prediction were found as 83.3%, 30.8%, 57.1%, and 93.8%, respectively (Figure 1).

DISCUSSION

In the literature, a debate about the role of hemogram parameters on the pathogenesis of stroke is still going on. In this study, we

Table 2a. Evaluation of the post-treatment status of the patients

	Complication (-)		Complication (+)		P
	Min-max	Median	Min-max	Median	
NIHSS score at admission	4.0-22.0	10.0	4.0-42.0	16.0	0.001 ^m
NIHSS score at discharge	0.0-22.0	8.0	3.0-35.0	16.5	0.001 ^m
mRS score	0.0-6.0	4.0	0.0-6.0	5.0	0.008 ^m
HGB	75.0-169.0	131.0	77.0-189.0	138.5	0.331 ^t
PLT	97.0-592.0	219.0	101.0-609.0	221.5	0.945 ^m
NLR	0.4-15.4	2.4	0.4-15.5	2.4	0.751 ^m
PLR	14.5-397.3	101.8	13.8-388.6	101.5	0.444 ^m
RDW	64.0-218.0	139.0	63.0-221.0	139.0	0.981 ^m
MPV	7.3-12.2	9.5	7.0-13.0	9.6	0.699 ^t
Lactate	0.8-7.0	1.7	1.1-7.7	1.9	0.421 ^m
Uric acid	1.8-11.5	5.3	2.6-13.3	8.2	0.897 ^t

HGB: haemoglobin, MPV: mean platelet volume, NIHSS: The National Institutes of Health Stroke Scale, mRS: The Modified Rankin Scale, NLR: neutrophil-to-lymphocyte ratio, PLR: platelet-to-lymphocyte ratio, PLT: platelet, RDW: red cell distribution width, ^mMann-Whitney U test/^tt-test

Table 2b. Evaluation of the post-treatment status of the patients

		Complication (-)	Complication (+)	P
		Mean ± SD/n (%)	Mean ± SD/n (%)	
Blood pressure	Normal	28 (26.7)	4 (16.7)	0.438 ^{x2}
	Stage I hypertension	24 (22.9)	8 (33.3)	
	Stage II hypertension	53 (50.5)	12 (50.0)	
ECG	NSR	74 (70.5)	15 (62.5)	0.446 ^{x2}
	AF	31 (29.5)	9 (37.5)	
ECHO findings				
Normal ECHO		68 (64.8)	18 (75.0)	0.471 ^{x2}
Enlarged right atrium and ventricle		7 (6.7)	2 (8.3)	
Enlarged left atrium and ventricle		19 (18.1)	3 (12.5)	
Segmentary wall motion abnormality		11 (10.5)	1 (4.2)	0.025 ^{x2}
One-month mortality	(+)	21 (20.0)	10 (41.7)	
	(-)	84 (80.0)	14 (58.3)	
Duration of treatment (min)	0-59	13 (12.4)	2 (8.3)	0.085 ^{x2}
	120	51 (48.6)	9 (37.5)	
	180	26 (24.8)	12 (50.0)	
	240	15 (14.3)	1 (4.2)	

AF: atrial fibrillation, ECG: electrocardiogram, ECHO: echocardiogram, NSR: normal sinus rhythm, ^{x2}Spearman Rho test

Table 3. Logistic regression analysis

	Univariate model			Multivariate model		
	OR	95% CI	p	OR	95% CI	p
NIHSS score at admission	1.164	1.059-1.279	0.002	-	-	-
NIHSS score at discharge	1.179	1.079-1.288	0.001	1.179	1.079 - 1.288	0.001
mRS score	1.532	1.088-2.156	0.014	-	-	-

NIHSS: The National Institutes of Health Stroke Scale, OR: odds ratio, CI: confidence interval




Figure 1. Sensitivity and specificity of NIHSS in predicting complication
NIHSS: The National Institutes of Health Stroke Scale

investigated the relationship between serum uric acid, lactate and MPV values and treatment success in patients with IS. Moreover, common scales which measured the disability of the patient after stroke and severity of the stroke, including NIHSS and mRS were analysed with regards to the presence of the complications after treatment.

Previously, it was reported that the hematologic parameters were significantly altered in patients with IS (17). Yigit et al. (18) indicated that anaemia was a risk factor for recurrence of IS in patients with malignancy. Another study reported that MPV was associated with the severity of acute IS (19). On the other hand, increased NLR at the admission was reported to be an independent factor related to poor prognosis and poor 90-day outcome in patients with intracerebral haemorrhage (ICH) and it was suggested to be a prognostic marker in spontaneous ICH patients (20). In our study, no significant differences in terms of haematological parameters evaluated between the patients with and without complications after TT were found.

Lactate is produced as the result of anaerobic glycolysis. When the glucose is deprived in the brain, lactate is used as an alternative energy source for the metabolic activities in the brain (21). Previously, elevated blood lactate levels in stroke patients at admission were suggested to indicate higher risk of 1-, 3-, and 12-month mortality (22). Another study, it was shown that lactate

level in cerebrospinal fluid (CSF), but not in blood, was found to be significantly higher in patients with acute stroke and it was suggested that CSF lactate level might be used as a marker for the evaluation of stroke severity (23). We also found no significant differences between the patients with and without complications with regards to serum lactate levels.

Hyperuricemia and accompanying dyslipidaemia in patients with acute stroke have been implicated to be risk factors for acute IS (24,25). Post-ischemic hyperuricemia in diabetic patients was reported to be associated with mortality and recurrent vascular events in IS patients (26). Moreover, Karagiannis et al. (27) reported a significant association between increased serum uric acid levels and early mortality. However, we did not find any significant differences in terms of uric acid levels between the patients who developed complications and the patients who did not develop complications.

Early recanalization positively affects the prognosis in patients with acute IS (28) by reducing the mortality and disability in the patients (29). Although, the risk of development of complications after intravenous recombinant tissue plasminogen activator treatment was reported to increase with older, presence of severe neurological deficit, hypertension, diabetes mellitus, and early signs of infarction in computed tomography, there were contradictory results regarding those (30-33). High NIHSS score before the TT has been implicated to be a risk factor for haemorrhagic transformation after TT (34,35). Moreover, NIHSS score higher than 25 is a contraindication for TT (33). The most common and serious complication of TT is haemorrhagic transformation and poor clinical prognosis is encountered in case of intracranial haemorrhage (36,37). The mRS is used to measure the disability of the patient after IS and is indicated to be an important tool for prediction outcomes after discharge (38-40). In our study, patients who developed complications after TT had higher NIHSS scores both at admission and at discharge, as well as higher mRS scores. Moreover, in the univariate model, significant efficacies of NIHSS scores both at admission and at discharge, as well as mRS scores were detected. On the other hand, NIHSS score at discharge was found to be a sensitive and specific predictor of development of complication in IS patients.

Study Limitations

This study had some limitations. First, the sample size was small, therefore, a larger group of patients could be included. Secondly, we did not measure the lactate levels in CSF or did not perform magnetic resonance spectroscopy analysis for the patients.

CONCLUSION

Predicting the development of complications after TT in patients with acute IS is crucial to prevent the complications and mortality. In the present study, NIHSS score was found to be a significant determinant in predicting complications in patients with IS. Therefore, NIHSS score may be suggested to be useful for the prediction of the development of the complications in the patients with IS. Future studies with larger populations and more detailed examinations are required to investigate the relationship between the parameters and complications and to predict the prognosis.

Ethics Committee Approval: This study was conducted in accordance with the Declaration of Helsinki on Ethical Principles. Ethical approval was obtained from University of Health Sciences Turkey, Şişli Hamidiye Etfal Training and Research Hospital Clinical Research Ethics Committee (decision no: 2688, date: 25.02.2020).

Informed Consent: Retrospective study.

Peer-review: Externally and internally peer-reviewed.

Author Contributions: Surgical and Medical Practices - D.Ö.; Concept - D.Ö.; Design - M.Ç.; Data Collection and/or Processing - D.Ö.; Analysis and/or Interpretation - M.Ç.; Literature Search - D.Ö., M.Ç.; Writing - M.Ç.

Conflict of Interest: The authors have no conflict of interest to declare.

Financial Disclosure: The authors declared that this study has received no financial support.

Etik Komite Onayı: Bu çalışma Helsinki Bildirgesi Etik İlkelerine uygun olarak yapılmıştır. Etik onay Sağlık Bilimleri Üniversitesi, Şişli Hamidiye Etfal Eğitim ve Araştırma Hastanesi Klinik Araştırmalar Etik Kurulu'ndan (karar no: 2688, tarih: 25.02.2020) alınmıştır.

Hasta Onamı: Retrospektif çalışma.

Hakem Değerlendirmesi: Editörler kurulu ve editörler kurulu dışında olan kişiler tarafından değerlendirilmiştir.

Yazar Katkıları: Cerrahi ve Medikal Uygulama - D.Ö.; Konsept - D.Ö.; Dizayn - M.Ç.; Veri Toplama veya İşleme - D.Ö.; Analiz veya Yorumlama - M.Ç.; Literatür Arama - D.Ö., M.Ç.; Yazan - M.Ç.

Çıkar Çatışması: Yazarlar tarafından çıkar çatışması bildirilmemiştir.

Finansal Destek: Yazarlar tarafından finansal destek almadıkları bildirilmiştir.

REFERENCES

- Goyal M, Ospel JM, Kappelhof M, Ganesh A. Challenges of Outcome Prediction for Acute Stroke Treatment Decisions. *Stroke* 2021; 52: 1921-8.
- Katan M, Luft A. Global Burden of Stroke. *Semin Neurol* 2018; 38: 208-11.
- Slawski D, Heit JJ. Treatment Challenges in Acute Minor Ischemic Stroke. *Front Neurol*. 2021; 12: 723637.
- Ma M, Wang L, Huang W, Zhong X, Li L, Wang H, et al. Meta-analysis of the correlation between serum uric acid level and carotid intima-media thickness. *PLoS One* 2021; 16: e0246416.
- Rahimi-Sakak F, Maroofi M, Rahmani J, Bellissimo N, Hekmatdoost A. Serum uric acid and risk of cardiovascular mortality: a systematic review and dose-response meta-analysis of cohort studies of over a million participants. *BMC Cardiovasc Disord* 2019; 19: 218.
- Soltani Z, Rasheed K, Kapusta DR, Reisin E. Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? *Curr Hypertens Rep* 2013; 15: 175-81.
- Hjortnaes J, Algra A, Olijhoek J, Huisman M, Jacobs J, van der Graaf Y, et al. Serum uric acid levels and risk for vascular diseases in patients with metabolic syndrome. *J Rheumatol* 2007; 34: 1882-7.
- Mapoure YN, Ayeah CM, Doualla MS, Ba H, Ngahane HBM, Mbahe S, et al. Serum Uric Acid Is Associated with Poor Outcome in Black Africans in the Acute Phase of Stroke. *Stroke Res Treat* 2017; 2017: 1935136.
- Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. *Proc Natl Acad Sci U S A* 1981; 78: 6858-62.
- Fabbrini E, Serafini M, Colic Baric I, Hazen SL, Klein S. Effect of plasma uric acid on antioxidant capacity, oxidative stress, and insulin sensitivity in obese subjects. *Diabetes* 2014; 63: 976-81.
- Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH. Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. *Arthritis Rheum* 2009; 61: 225-32.
- Meregalli A, Oliveira RP, Friedman G. Occult hypoperfusion is associated with increased mortality in hemodynamically stable, high-risk, surgical patients. *Crit Care* 2004; 8: R60-5.
- Kushimoto S, Akaishi S, Sato T, Nomura R, Fujita M, Kudo D, et al. Lactate, a useful marker for disease mortality and severity but an unreliable marker of tissue hypoxia/hypoperfusion in critically ill patients. *Acute Med Surg* 2016; 3: 293-7.
- Bakker J, Nijsten MW, Jansen TC. Clinical use of lactate monitoring in critically ill patients. *Ann Intensive Care* 2013; 3: 12.
- Henriksen O, Gideon P, Sperling B, Olsen TS, Jørgensen HS, Arlien-Søborg P. Cerebral lactate production and blood flow in acute stroke. *J Magn Reson Imaging* 1992; 2: 511-7.
- Rostami E, Engquist H, Howells T, Johnson U, Ronne-Engström E, Nilsson P, et al. Early low cerebral blood flow and high cerebral lactate: prediction of delayed cerebral ischemia in subarachnoid hemorrhage. *J Neurosurg* 2018; 128: 1762-70.
- Sharif S, Ghaffar S, Saqib M, Naz S. Analysis of Hematological Parameters in Patients with Ischemic Stroke. *Endocrinol Metab Int J* 2020; 8: 17-20.
- Yigit M, Sogut O, Yigit E, Turkdogan KA, Kaplan O, Dur A, et al. The relationship between anemia and recurrence of ischemic stroke in patients with Trousseau's syndrome: A retrospective cross-sectional study. *Turk J Emerg Med* 2016; 16: 65-8.
- Ghahremanfard F, Asghari N, Ghorbani R, Samaei A, Ghomi H, Tamadon M. The relationship between mean platelet volume and severity of acute ischemic brain stroke. *Neurosciences (Riyadh)* 2013; 18: 147-51.
- Menon G, Johnson SE, Hegde A, Rathod S, Nayak R, Nair R. Neutrophil to lymphocyte ratio - A novel prognostic marker following spontaneous intracerebral haemorrhage. *Clin Neurol Neurosurg* 2021; 200: 106339.
- Wyss MT, Jolivet R, Buck A, Magistretti PJ, Weber B. In vivo evidence for lactate as a neuronal energy source. *J Neurosci* 2011; 31: 7477-85.
- Sakal C, Ak R, Taşçı A, Kirkpantur ED, Ünal Akoğlu E, Cimilli Ozturk T. Admission blood lactate levels of patients diagnosed with cerebrovascular disease effects on short- and long-term mortality risk. *Int J Clin Pract* 2021; 75: e14161.
- Brouns R, Sheorajpanday R, Wauters A, De Surgeloose D, Mariën P, De Deyn PP. Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. *Clin Chim Acta* 2008; 397: 27-31.
- Arora T, Mantur PG, Bidri RC, Mulimani MS. Serum Uric Acid Levels and Serum Lipid Levels in Patients with Ischemic Cerebrovascular Accident. *J Assoc Physicians India* 2018; 66: 66-8.
- Mehrpour M, Khuzan M, Najimi N, Motamed MR, Fereshtehnejad SM. Serum uric acid level in acute stroke patients. *Med J Islam Repub Iran* 2012; 26: 66-72.
- Newman EJ, Rahman FS, Lees KR, Weir CJ, Walters MR. Elevated serum urate concentration independently predicts poor outcome following stroke in patients with diabetes. *Diabetes Metab Res Rev* 2006; 22: 79-82.
- Karagiannis A, Mikhailidis DP, Tziomalos K, Sileli M, Savvatanos S, Kakafika A, et al. Serum uric acid as an independent predictor of early death after acute stroke. *Circ J* 2007; 71: 1120-7.
- Tsivgoulis G, Saqqur M, Sharma VK, Brunser A, Eggers J, Mikulik R, et al. Timing of Recanalization and Functional Recovery in Acute Ischemic Stroke. *J Stroke* 2020; 22: 130-40.
- Wardlaw JM, Murray V, Berge E, del Zoppo GJ. Thrombolysis for acute ischaemic stroke. *Cochrane Database Syst Rev* 2014; 2014: CD000213.
- Larrue V, von Kummer R R, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the

- European-Australasian Acute Stroke Study (ECASS II). *Stroke* 2001; 32: 438-41.
31. Jaillard A, Cornu C, Durieux A, Moulin T, Boutitie F, Lees KR, et al. Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. *Stroke* 1999; 30: 1326-32.
 32. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. *Stroke* 1997; 28: 957-60.
 33. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. *Stroke* 1997; 28: 2109-18.
 34. Aviv RI, d'Esterre CD, Murphy BD, Hopyan JJ, Buck B, Mallia G, et al. Hemorrhagic transformation of ischemic stroke: prediction with CT perfusion. *Radiology* 2009; 250: 867-77.
 35. Singer OC, Berkefeld J, Lorenz MW, Fiehler J, Albers GW, Lansberg MG, et al. Risk of symptomatic intracerebral hemorrhage in patients treated with intra-arterial thrombolysis. *Cerebrovasc Dis* 2009; 27: 368-74.
 36. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. *N Engl J Med* 2008; 359: 1317-29.
 37. Zhang X, Yu Y, Jiang L, Chen T, Sang Y, Wang Y, et al. The risk factors of early hemorrhage after emergency intravenous thrombolysis in patients with acute ischemic stroke. *Ann Palliat Med* 2021; 10: 5706-13.
 38. Rangaraju S, Haussen D, Nogueira RG, Nahab F, Frankel M. Comparison of 3-Month Stroke Disability and Quality of Life across Modified Rankin Scale Categories. *Interv Neurol* 2017; 6: 36-41.
 39. ElHabr AK, Katz JM, Wang J, Bastani M, Martinez G, Gribko M, et al. Predicting 90-day modified Rankin Scale score with discharge information in acute ischaemic stroke patients following treatment. *BMJ Neurol Open* 2021; 3: e000177.
 40. Kim SE, Lee H, Kim JY, Lee KJ, Kang J, Kim BJ, et al. Three-month modified Rankin Scale as a determinant of 5-year cumulative costs after ischemic stroke: An analysis of 11,136 patients in Korea. *Neurology* 2020; 94: e978-e91.